Mapping the effectiveness and risks of GLP-1 receptor agonistsYan Xie(Washington University in St. Louis), Ziyad Al‐Aly(Washington University in St. Louis), Taeyoung Choi(VA St. Louis Health Care System)Nature MedicineJanuary 20, 202510.1038/s41591-024-03412-wCited by 240SaveCiteExport RISWatch citationsRelated PapersGlobal, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017|The Lancet|2018|14kGlobal, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016|The Lancet|2017|13.5kGlobal, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980–2017: a systematic analysis for the Global Burden of Disease Study 2017|The Lancet|2018|8.7kGlobal, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016|The Lancet|2017|4.9kGlobal incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 2021|The Lancet|2024|4.4k